BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)
Phase 1b/2aActive
Key Facts
Indication
Oculopharyngeal Muscular Dystrophy (OPMD)
Phase
Phase 1b/2a
Status
Active
Company
About Benitec Biopharma
Benitec Biopharma Inc. is a clinical-stage biotech focused on developing transformative, single-administration genetic medicines for chronic and life-threatening conditions. Its proprietary ddRNAi platform is designed to permanently silence disease-causing genes by integrating RNAi into a gene therapy vector. The company's most advanced program, BB-301 for OPMD, is in Phase 1b/2a trials and has shown positive interim results, positioning Benitec as a leader in next-generation gene silencing therapeutics.
View full company profile